Clinical efficacy and safety of zoledronic acid in osteoporosis and Paget’s bone disease

References

• Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am. J. Obstets. Gynecol.194, S3–S11 (2006).
   PubMed Web of Science ®Google Scholar
• Ismail AA, Pye SR, Cockerill WC et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos. Int.13, 565–571 (2002).
   PubMed Web of Science ®Google Scholar
• Fujita T. Osteoporosis in Japan: factors contributing to the low incidence of hip fractures. Adv. Nutr. Res.9, 89–99 (1994).
   PubMedGoogle Scholar
• Gennari L, Khosla S, Bilezian JP. Estrogen and fracture risk in men. J. Bone Miner. Res.23, 1548–1551 (2008).
   PubMed Web of Science ®Google Scholar
• Eriksen EF, Hodgson SF, Eastell R et al. Cancellous bone remodeling in type I (post-menopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Miner. Res.5, 311–319 (1990).
   PubMed Web of Science ®Google Scholar
• Cooper C, Harvey NC, Dennison EM, van Staa TP. Update on the epidemiology of Paget’s disease of the bone. J. Bone Miner. Res.21(Suppl. 2), P3–P8 (2006).
   PubMed Web of Science ®Google Scholar
• Penning-van Beast FJ, Goettsch WG, Erkens JA, Herrings RM. Determinants of persistence with bisphosphonates – a study in women with postmenopausal osteoporosis. Clin. Ther.28, 236–242 (2006).
   PubMedGoogle Scholar
• McCombs JS, Thiebaud B, Mclaughlin-Miley C, Shi J. Compliance with drugs therapies for the treatment and prevention of osteoporosis. Maturitas48, 271–287 (2004).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Rabenda V, Neuprez A. Adherence, patients preference and dosing frequency: understanding the relationship. Bone38, S2–S6 (2006).
   PubMedGoogle Scholar
• Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med.346, 653–661 (2002).
   PubMed Web of Science ®Google Scholar
• Devogelaer JP, Brown JP, Burckhardt P et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos. Int.18, 1211–1218 (2007).
   PubMed Web of Science ®Google Scholar
• Borba VZ, Paz-Filho G, Kulak CA, Seilbel MJ, Bilezikian JP. Bone turnover 18 months after a single intravenous dose of zoledronic acid. Int. J. Clin. Pract.61, 1058–1062 (2007).
   PubMedGoogle Scholar
• Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med.356, 1809–1822 (2007).
   PubMed Web of Science ®Google Scholar
• McClung M, Recker R, Miller P et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone41, 122–128 (2007).
   PubMed Web of Science ®Google Scholar
• Colón-Emetic C, Kuchibhatia M, Pieper C et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos. Int.14, 879–883 (2003).
   PubMedGoogle Scholar
• Rabenda V, Vancoverloop J, Fabri V et al. Low incidence of anti-osteoporosis treatment after hip fracture. J. Bone Joint Surg. Am.90, 2142–2148 (2008).
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colón-Emetic CS, Magaziner JS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med.357, 1799–1809 (2007).
   PubMed Web of Science ®Google Scholar
• Maclean C, Newberry S, Maglioned M et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann. Intern. Med.148, 197–213 (2008).
   PubMed Web of Science ®Google Scholar
• Reid DM, Devogelaer JP, Saag K et al. Zoledronic acid and risendronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet373, 1253–1263 (2009).
   PubMed Web of Science ®Google Scholar
• Bia M. Evaluation of bone disease and fractures post transplant. Transplant Rev. (Orlando)22, 52–61 (2008).
   PubMedGoogle Scholar
• Monegral A, Navasa M, Guanabens N et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporosis12, 484–492 (2001).
   PubMedGoogle Scholar
• Crawford BAL, Kam C, Pavlovic et al. Zoledronic acid prevents bone loss after liver transplantation – a randomised, double-blind, placebo-controlled trial. Ann. Intern. Med.144, 239–248 (2006).
   PubMed Web of Science ®Google Scholar
• Haas M, Leko-Mohr A, Roschger P et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int.63, 1130–1136 (2003).
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mitterbauser C, Heinze B et al. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int.65, 304–309 (2004).
   PubMedGoogle Scholar
• Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol. Blood Marrow Transplant.6, 165–174 (2000).
   PubMed Web of Science ®Google Scholar
• Tauchmanovà L, Serio B, Del Puente A et al. Long-lasting bone damage detected by dual energy x-ray absorptiometry, phalangeal osteosonogrammetry and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J. Clin. Endocrinol. Metab.87, 5059–5065 (2002).
   Google Scholar
• Tauchmanovà L, Ricci P, Serio B et al. Short-term zoledronic acid and treatment increases bone mineral density and marrow clonogenic fibroblast progenitors and allogeneic stem cell transplantation. J. Clin. Endocrinol. Metab.90, 627–634 (2005).
   PubMed Web of Science ®Google Scholar
• Tauchmanovà L, De Simone G, Mussella T et al. Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant.37, 81–88 (2006).
   PubMed Web of Science ®Google Scholar
• Di Matteo R, Liuzza F, Manicone PF et al. Bone and maxillofacial abnormalities in thalassemia: a review of the literature. J. Biol. Regul. Homeost. Agents22, 211–216 (2008).
   PubMedGoogle Scholar
• Otrock ZK, Azar ST, Shamseddeen WA et al. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a Phase II clinical trial. Ann. Hematol.85, 605–609 (2006).
   PubMedGoogle Scholar
• Perifanis V, Vyzantiadis T, Tziomalos K et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with β-thalassaemia. Ann. Haematol.86, 23–30 (2007).
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Anagnostopoulus A, Kontantopoulos K et al. Zoledronic acid for the treatment of osteoporosis in patients with β-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica91, 1193–1202 (2006).
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Christoulas D, Konstantinidou M et al. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation, in patients with thalassemia-induced osteoporosis: placebo-controlled trial. Haematologica93, 1588–1590 (2008).
   PubMedGoogle Scholar
• Gilfillan CP, Strauss BJS, Rodda CP et al. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif. Tissue Int.79, 138–144 (2006).
   PubMedGoogle Scholar
• Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch. Intern. Med.165, 1743–1748 (2005).
   PubMed Web of Science ®Google Scholar
• Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology65, 811–816 (2005).
   Google Scholar
• Poole KE, Loveridge N, Rose CM, Warburton EA, Reeve J. A single infusion of zoledronate prevents bone loss after stroke. Stroke38, 1519–1525 (2007).
   PubMed Web of Science ®Google Scholar
• Gilchrist NL, Frampton CM, Acland RH et al. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab.92, 1385–1390 (2007).
   PubMed Web of Science ®Google Scholar
• Shapiro J, Smith B, Beck T et al. Treatment with zoledronic acid ameloriates negative geometric changes in the proximal femur following acute spinal cord injury. Calcif. Tissue Int.80, 316–322 (2007).
   PubMed Web of Science ®Google Scholar
• Amorosa V, Tebas P. Bone disease and HIV infection. Clin. Infect. Dis.42, 108–114 (2006).
   PubMed Web of Science ®Google Scholar
• Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J. Clin. Endocrinol. Metab.93, 3499–3504 (2008).
   PubMed Web of Science ®Google Scholar
• McComsey GA, Kendal MA, Tebas P et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS21, 2473–2482 (2007).
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Grey AB, Horne AM et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J. Clin. Endocrinol. Metab.92, 1283–1288 (2007).
   PubMed Web of Science ®Google Scholar
• Pepe J, Petrucci MT, Nofroni I et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br. J. Haematol.134, 485–490.
   PubMedGoogle Scholar
• Berenson JR, Yellin O, Boccia RV et al. Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clin. Cancer Res.14, 6289–6295 (2008).
   PubMed Web of Science ®Google Scholar
• Jarrett SJ, Conaghan PG, Sloan VS et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arhthritis Rheum.54, 1410–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Arden-Cordone M, Siris ES, Lyles KW et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget’s disease of bone. Calcif. Tissue Int.60, 415–418 (1997).
   PubMed Web of Science ®Google Scholar
• Reid IR, Miller P, Lyles K et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N. Engl. J. Med.353, 898–908 (2005).
   PubMed Web of Science ®Google Scholar
• Hosking D, Lyles K, Brown JP et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J. Bone Miner. Res.22, 142–148 (2007).
   PubMed Web of Science ®Google Scholar
• Merlotti D, Gennari L, Martini G et al. Comparison of different bisphosphonates regimens for Paget’s disease of bone. J. Bone Miner. Res.22, 1510–1517 (2007).
   PubMed Web of Science ®Google Scholar
• Grbic JT, Landesberg R, Lin SQ et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J. Am. Dent. Assoc.139, 32–40 (2008).
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J et al. Editorial: bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res.22, 1479–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med.344, 1434–1441 (2001).
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP et al. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis – a randomized trial. Arch. Intern. Med.146, 326–339 (2007).
   Google Scholar
• Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch. Intern. Med.168, 826–831 (2008).
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Christensen S, Mehnert F et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case–control study. BMJ336, 813–816 (2008).
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients with oral bisphosphonates. J. Intern. Med.265(5), 581–592 (2009).
   PubMed Web of Science ®Google Scholar
• Grotz W, Nagel C, Poeschiel D et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J. Am. Soc. Nephrol.12, 1530–1537 (2001).
   PubMed Web of Science ®Google Scholar
• Monegal A, Guanabens N, Suárez MJ et al. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl. Int.22(2), 198–206 (2008).
   PubMedGoogle Scholar
• Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J. Am. Soc. Nephrol.14, 2669–2676 (2003).
   PubMed Web of Science ®Google Scholar
• Kananen K, Volin L, Laitinen K et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J. Clin. Endocrinol. Metab.90, 3877–3885 (2005).
   PubMed Web of Science ®Google Scholar
• Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone disease. J. Clin. Densitom.11, 325–338 (2008).
   PubMed Web of Science ®Google Scholar